中国组织工程研究
中國組織工程研究
중국조직공정연구
Journal of Clinical Rehabilitative Tissue Engineering Research
2015年
38期
6179-6183
,共5页
李晓利%牛敏%张铭%张娜娜%施瑶
李曉利%牛敏%張銘%張娜娜%施瑤
리효리%우민%장명%장나나%시요
生物材料%纳米材料%药物控释材料%聚乳酸载药纳米微粒%小鼠胃癌细胞株%体外杀伤%5-氟尿嘧啶%抑制率浓度%生长抑制能力%诱导作用%生物半衰期
生物材料%納米材料%藥物控釋材料%聚乳痠載藥納米微粒%小鼠胃癌細胞株%體外殺傷%5-氟尿嘧啶%抑製率濃度%生長抑製能力%誘導作用%生物半衰期
생물재료%납미재료%약물공석재료%취유산재약납미미립%소서위암세포주%체외살상%5-불뇨밀정%억제솔농도%생장억제능력%유도작용%생물반쇠기
背景：5-氟尿嘧啶在胃癌治疗中占据重要地位，但是长期服用容易出现骨髓抑制、白细胞减少等不良反应。聚乳酸及共聚物载药微粒材料生物相容性较高，分解物不会在机体内发生聚集。<br> 目的：探讨聚乳酸载药纳米微粒对胃癌细胞株的体外杀伤作用机制。<br> 方法：选取10只小鼠进行实验，利用超声乳化方法制备5-氟尿嘧啶聚乳酸载药纳米微粒，并采用噻唑蓝比色法配制1×10-7，1×10-6，1×10-5，1×10-4 mol/L的5-氟尿嘧啶聚乳酸载药纳米微粒，检测其对小鼠胃癌细胞的体外杀伤效应，并且计算出药物的抑制率浓度以及对胃癌细胞的生长抑制能力等以及凋亡的诱导作用。<br> 结果与结论：透射电镜下观察5-氟尿嘧啶聚乳酸载药纳米微粒：形态完好，分布相对均匀，不出现粘连等现象，用药24 h药物浓度可达到50%，72 h后能够达到62.9%；不同浓度下单一5-氟尿嘧啶和5-氟尿嘧啶聚乳酸载药纳米微粒和小鼠胃癌细胞联合培养48 h后，细胞的活性随着药物浓度的提高出现下降趋势，并且5-氟尿嘧啶聚乳酸载药纳米微粒细胞抑制能力显著高于5-氟尿嘧啶(P <0.05)；5-氟尿嘧啶聚乳酸载药纳米微粒的IC50显著低于5-氟尿嘧啶(P <0.05)。结果证实聚乳酸纳米微粒具有优良的药物载体作用，载药量较大，在机体内提高药物浓度，并且不降低5-氟尿嘧啶成分的生物学活性，可为胃癌治疗提供新思路。
揹景：5-氟尿嘧啶在胃癌治療中佔據重要地位，但是長期服用容易齣現骨髓抑製、白細胞減少等不良反應。聚乳痠及共聚物載藥微粒材料生物相容性較高，分解物不會在機體內髮生聚集。<br> 目的：探討聚乳痠載藥納米微粒對胃癌細胞株的體外殺傷作用機製。<br> 方法：選取10隻小鼠進行實驗，利用超聲乳化方法製備5-氟尿嘧啶聚乳痠載藥納米微粒，併採用噻唑藍比色法配製1×10-7，1×10-6，1×10-5，1×10-4 mol/L的5-氟尿嘧啶聚乳痠載藥納米微粒，檢測其對小鼠胃癌細胞的體外殺傷效應，併且計算齣藥物的抑製率濃度以及對胃癌細胞的生長抑製能力等以及凋亡的誘導作用。<br> 結果與結論：透射電鏡下觀察5-氟尿嘧啶聚乳痠載藥納米微粒：形態完好，分佈相對均勻，不齣現粘連等現象，用藥24 h藥物濃度可達到50%，72 h後能夠達到62.9%；不同濃度下單一5-氟尿嘧啶和5-氟尿嘧啶聚乳痠載藥納米微粒和小鼠胃癌細胞聯閤培養48 h後，細胞的活性隨著藥物濃度的提高齣現下降趨勢，併且5-氟尿嘧啶聚乳痠載藥納米微粒細胞抑製能力顯著高于5-氟尿嘧啶(P <0.05)；5-氟尿嘧啶聚乳痠載藥納米微粒的IC50顯著低于5-氟尿嘧啶(P <0.05)。結果證實聚乳痠納米微粒具有優良的藥物載體作用，載藥量較大，在機體內提高藥物濃度，併且不降低5-氟尿嘧啶成分的生物學活性，可為胃癌治療提供新思路。
배경：5-불뇨밀정재위암치료중점거중요지위，단시장기복용용역출현골수억제、백세포감소등불량반응。취유산급공취물재약미립재료생물상용성교고，분해물불회재궤체내발생취집。<br> 목적：탐토취유산재약납미미립대위암세포주적체외살상작용궤제。<br> 방법：선취10지소서진행실험，이용초성유화방법제비5-불뇨밀정취유산재약납미미립，병채용새서람비색법배제1×10-7，1×10-6，1×10-5，1×10-4 mol/L적5-불뇨밀정취유산재약납미미립，검측기대소서위암세포적체외살상효응，병차계산출약물적억제솔농도이급대위암세포적생장억제능력등이급조망적유도작용。<br> 결과여결론：투사전경하관찰5-불뇨밀정취유산재약납미미립：형태완호，분포상대균균，불출현점련등현상，용약24 h약물농도가체도50%，72 h후능구체도62.9%；불동농도하단일5-불뇨밀정화5-불뇨밀정취유산재약납미미립화소서위암세포연합배양48 h후，세포적활성수착약물농도적제고출현하강추세，병차5-불뇨밀정취유산재약납미미립세포억제능력현저고우5-불뇨밀정(P <0.05)；5-불뇨밀정취유산재약납미미립적IC50현저저우5-불뇨밀정(P <0.05)。결과증실취유산납미미립구유우량적약물재체작용，재약량교대，재궤체내제고약물농도，병차불강저5-불뇨밀정성분적생물학활성，가위위암치료제공신사로。
BACKGROUND:5-Fluorouracil occupies an important position in the treatment of gastric cancer, but its long-term use can easily induce adverse reactions such as myelosuppression and leukopenia. Polylactic acid and its copolymers have a higher biocompatibility, and their decomposer cannot gather in the body. <br> OBJECTIVE:To investigate the in vitro cytotoxicity mechanism of 5-fluorouracil-loaded polylactic acid nanoparticles on gastric cancer cel lines. <br> METHODS:Ten mice were selected in this study. 5-fluorouracil-loaded polylactic acid nanoparticles (1×10-7, 1×10-6, 1×10-5, 1×10-4 mol/L) were prepared using ultrasonic emulsification method. Kiling effect of polylactic acid nanoparticles on gastric cancer cel lines in vitrowere detected. Then, the inhibition rate was calculated at different concentrations. <br> RESULTS AND CONCLUSIONS: Under the transmission electron microscope, 5-fluorouracil-loaded polylactic acid nanoparticles had good shape and relatively evenly distributed with no adhesions. After drug administration, the drug concentration was 50% at 24 hours and 62.9% at 72 hours. After 48 hours co-culture with single 5-fluorouracil or 5-fluorouracil-loaded polylactic acid nanoparticles, the viability of gastric cancer cels showed a decrease trend with the increase of drug concentrations, and moreover, 5-fluorouracil-loaded polylactic acid nanoparticles had a better cel inhibition ability than the single 5-fluorouracil (P < 0.05). The IC50value of 5-fluorouracil-loaded polylactic acid nanoparticles was significantly lower than that of 5-fluorouracil (P < 0.05). These findings indicate that polylactic acid nanoparticles as good drug carriers have a strong drug loading capacity and increase drug concentration in the body, but cannot reduce the biological activity of 5-fluorouracil, which provide new ideas for the treatment of gastric cancer.
